Reports, Notices, Documents

Proposed Amendment To Section 25705 Specific Regulatory Levels Posing No Significant Risk: Imazalil

09/23/2011

Comment Period - Proposed Amendment To Section 25705 Specific Regulatory Levels Posing No Significant Risk: Imazalil

09/23/2011

Notice of Withdrawal and Resubmittal of Proposed Rulemaking Amendment to Section 25705 Specific Regulatory Levels Posing No Significant Risk: Imazalil

09/23/2011

Comments on Proposed Modified Regulation

09/22/2011

Comment Period - Proposed Amendment To Section 25707(B), Route of Exposure: Hexavalent Chromium (VI)

09/16/2011

Notice of Intent to List Chemicals: Estrogen–progestogen (combined) used as menopausal therapy, Etoposide, Etoposide in combination with cisplatin and bleomycin, Methyl isobutyl ketone, MOPP (vincristine-prednisone-nitrogen mustard-procarbazine mixture)

09/16/2011

Proposed Amendment To Section 25707(B), Route of Exposure: Hexavalent Chromium (VI)

09/16/2011

Original Proposed Amendment to Section 25705 Specific Regulatory Levels Posing No Significant Risk: Imazalil

09/09/2011

Proposed Amendment of Section 25903 Notices of Violation

09/02/2011

Chemical Listed Effective September 2, 2011 as Known to the State of California to Cause Cancer: titanium dioxide (airborne, unbound particles of respirable size)

09/02/2011